Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability (Q45824130)

16 December 2017

title

Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability (English)

1 reference

16 December 2017

1 reference

M Freidel

1

1 reference

16 December 2017

K Tiel-Wilck

2

1 reference

16 December 2017

H Schreiber

3

1 reference

16 December 2017

A Prechtl

4

1 reference

16 December 2017

U Essner

5

1 reference

16 December 2017

M Lang

6

1 reference

16 December 2017

language of work or name

English

0 references

publication date

11 September 2014

1 reference

16 December 2017

Acta Neurologica Scandinavica

published in

1 reference

16 December 2017

volume

131

1 reference

16 December 2017

issue

1

1 reference

16 December 2017

page(s)

9-16

1 reference

16 December 2017

The epidemiology of multiple sclerosis in Europe.

cites work

1 reference

Natural history of multiple sclerosis symptoms

21 January 2018

1 reference

Prevalence and treatment of spasticity reported by multiple sclerosis patients

21 January 2018

1 reference

Spasticity in patients with multiple sclerosis--clinical characteristics, treatment and quality of life

21 January 2018

1 reference

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis

21 January 2018

1 reference

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

21 January 2018

1 reference

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

21 January 2018

1 reference

Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach

21 January 2018

1 reference

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).

21 January 2018

1 reference

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis

21 January 2018

1 reference

Adverse effects of medical cannabinoids: a systematic review

21 January 2018

1 reference

Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity

21 January 2018

1 reference

Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain

21 January 2018

1 reference

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale

21 January 2018

1 reference

Driving performance in persons with mild to moderate symptoms of multiple sclerosis.

21 January 2018

1 reference

The contribution of cognition and spasticity to driving performance in multiple sclerosis

21 January 2018

1 reference

Predictors of driving in individuals with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

Cognitive abilities as predictors of safety to drive in people with multiple sclerosis.

21 January 2018

1 reference

Examining the relationship between cognition and driving performance in multiple sclerosis.

21 January 2018

1 reference

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/ANE.12287

1 reference

16 December 2017

1 reference

16 December 2017